Drug monitoring and toxicology: A procedure for the monitoring of oxcarbazepine metabolite by HPLC-UV

Journal of Chromatographic Science

Volumn 44, Issue 1, 2006, Pages 45-48

  Juenke, JoEtta M ^a   Brown, Paul I ^a   Urry, Francis M ^a,b   McMillin, Gwendolyn A ^a,b  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DRUG DERIVATIVE; OXCARBAZEPINE;

ARTICLE; BLOOD; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; METHODOLOGY; REPRODUCIBILITY; STANDARD; ULTRAVIOLET SPECTROPHOTOMETRY; VALIDATION STUDY;

ANTICONVULSANTS; CARBAMAZEPINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; HUMANS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 33646840141     PISSN: 00219665     EISSN: 00219665     Source Type: Journal    
DOI: 10.1093/chromsci/44.1.45     Document Type: Article

References (33)

1. A. Volosov, S. Xiaodong, E. Perucca, B. Yagen, A. Sintov, and M. Bialer. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin. Pharmacol. Ther. 66(6): 547-53 (1999).
2. H. Flemming and L. Murray, Eds. Physicians' Desk Reference, 58th ed. Medical Economics Co., Montvale, NJ, 2004.
3. P. Lloyd, G. Flesch, and W. Dieterle. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 35(suppl 3): S10-3 (1994).
4. M. Dam and L.H. Ostergaard. "Oxcarbazepine". In Antiepileptic Drugs, 4th ed. R.H. Levy, R.H. Manson, and B.S. Meldrum, Eds. Raven Press, New York, NY, 1995, pp. 987-95.
5. L. Gram. "Oxcarbazepine". In Epilepsy: a Comprehensive Textbook. J. Engel and T.A. Pedley, Eds. Lippincott-Raven, Philadelphia, PA, 1997, pp. 1541-46.
6. E.S. Tecoma. Oxcarbazepine. Epilepsia 40(suppl 5): S37-46 (1999).
7. S. Shorvon. Oxcarbazepine: a review. Seizure 9(2): 75-79 (2000).
8. A. Beydoun and E. Kutluay. Oxcarbazepine. Expert Opin. Pharmacother. 3: 59-71 (2002).
9. A. Schulze-Bonhage and V. Homberg. Oxcarbazepine. Seizure 11: 73 (2002).
10. T.W. May, E. Korn-Merker, and B. Rambeck. Clinical pharmacokinetics of oxcarbazepine. Clin. Pharmacokinet. 42: 1023-42 (2003).
11. S.M. La Roche and S.L. Helmers. The new antiepileptic drugs: scientific review. J. Am. Med. Assoc. 291: 605-14 (2004).
12. W.M. Sallas, S. Milosavljev, J. D'souza, and M. Hossain. Pharmacokinetic drug interactions in children taking oxcarbazepine. Clin. Pharmacol. Ther. 74: 138-49 (2003).
13. P. Baird. The interactive metabolism effect of oxcarbazepine coadministered with tricyclic antidepressant therapy for OCD symptoms. J. Clin. Psychopharmacol. 23: 419-20 (2003).
14. N. Guenault, P. Odou, and H. Robert. Increase in the dihydroxycarbamazepine serum levels in patients co-medicated with oxcarbazepine and lamotrigine. Eur. J. Clin. Pharmacol. 59: 781-82 (2003).
15. L.M. Bang and K.L. Goa. Spotlight on oxcarbazepine in epilepsy. CNS Drugs 18: 57-61 (2004).
16. S. Nasr. Oxcarbazepine for mood disorders. Am. J. Psychiatry 159: 1793 (2002).
17. M.P. Gaudino, M.J. Smith, and D.T. Matthews. Use of oxcarbazepine for treatment-resistant aggression. Psychiatry Serv. 54: 1166-77 (2003).
18. T. Berigan. Oxcarbazepine treatment of post traumatic stress disorder. Can. J. Psychiatry 47: 973-74 (2002).
19. E. Carrazana and I. Mikoshiba. Rationale and evidence for the use of oxcarbazepine in neuropathic pain. J. Pain Symptom Manage 25(suppl 5): S31-5 (2003).
20. A. Beydoun, S.A. Kobetz, and E.J. Carrazana. Efficacy of oxcarbazepine in the treatment of painful diabetic neuropathy. Clin. J. Pain 20: 174-78 (2004).
21. S.N. Ghaemi, D.A. Berv, J. Klugman, K.J. Rosenquist, and D.J. Hsu. Oxcarbazepine treatment of bipolar disorder. J. Clin. Psychiatry 64: 943-45 (2003).
22. F.M. Leweke, C.W. Gerth, D. Koethe, J. Faulhaber, and J. Klosterkotter. Oxcarbazepine as an adjunct for schizophrenia. Am. J. Psychiatry 161: 1130-31 (2004).
23. P. Woster and E.J. Carrazana. Oxcarbazepine and hyponattremia. Am. J. Health Syst. Pharm. 59: 467 (2002).
24. R.C. Sachdeo, A. Wasserstein, P.J. Mesenbrink, and J. D'Souza. Effects of oxcarbazepine on sodium concentration and water handling. Ann. Neurol. 51: 613-20 (2002).
25. A.S. Cilli and E. Algun. Oxcarbazepine-induced syndrome of inappropriate secretion of antidiuretic hormone. J. Clin. Psychiatry 63: 742 (2002).
26. S.I. Johannessen, D. Battino, D.J. Berry, M. Bialer, G. Kramer, T. Tomson, and P.N. Patsalos. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther. Drug Monit. 25: 347-63 (2003).
27. M.L. Qi, P. Wang, L.J. Wang, and R.N. Fu. LC method for the determination of oxcarbazepine in pharmaceutical preparations. J. Pharm. Biomed. Anal. 31: 57-62 (2003).
28. V. Pucci, E. Kenndler, and M.A. Raggi. Quantitation of oxcarbazine and its metabolites in human plasma by micellar electrokinetic chromatography. Biomed. Chromatogr. 17: 231-38 (2003).
29. H.H. Maurer, C. Kratzch, A.A. Weber, F.T. Peters, and T. Kraemer. Validated assay for the quantification of oxcarbazepine and it's active dihydro metabolite 10-hydroxycarbazepine in plasma by atmospheric pressure chemical ionazation liquid chromatography/mass spectrometry. J. Mass Spectrom. 37: 687-92 (2002).
30. H. Levert, P. Odou, and H. Robert. LC determination of oxcarbazepine and its active metabolite in human serum. J. Pharm. Biomed Anal. 28: 517-25 (2002).
31. R. Mandrioli, N. Ghedini, F. Albani, E. Kenndler, and M.A. Raggi. Liquid chromatographic determination of oxcarbazepine and its metabolites in plasma of epileptic patients after solid phase extraction. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 783: 253-63 (2003).
32. C. Souppart, M. Decherf, H. Humbert, and G. Maurer. Development of a high throughput 96-well plate sample preparation method for the determination of trileptal (oxcarbazepine) and its metabolites in human plasma. J. Chromatogr. B Biomed .Sci. Appl. 762: 9-15 (2001).
33. Phenomenex 04/05 Catalog. Phenomenex, Torrance, CA, 2004, p. 245.